Faron Pharmaceuticals Oy (LSE:FARN) - Share price - Overview

Stock Report

Faron Pharmaceuticals Oy FARN

Last Price
GBX83.50

Day Change
-1.50|-1.76%

As of 19/07/2018
17:06:14 BST | GBX
Minimum 15 Minutes Delay.

Last Close85.00p
Day Range82.00 - 85.05
Mkt Cap-
52-Wk Range54.00 - 900.00
Yield %-
ISINFI4000153309
Volume68,497
P/E-114.70
P/SInfinity
P/CF-1.27

Share Price

Total Returns 19/07/2018

 Chg (%)  
More ...
Faron Pharmaceuticals Oy51.82 
FTSE 100 TR GBP1.18
 
Financials
201520162017
More ...
Income Statement
Turnover0.520.950.00
Operating Profit-5.84-9.70-19.77
Net Profit-6.19-10.14-21.06
Reported EPS-0.30-0.42-0.76
Balance Sheet
Current Assets13.7913.9513.23
Non Current Assets1.031.801.66
Total Assets14.8215.7514.89
Current Liabilities2.204.658.06
Total Liabilities3.647.3510.14
Total Equity11.188.404.74
Cash Flow
Operating Cash Flow-7.10-9.34-18.36
Net Change in Cash10.83-0.22-1.88
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
21/06/2018PurchaseDr. Markku Tapani Jalkanen71.0012,0008,520.00
21/06/2018PurchaseDr. Markku Tapani Jalkanen71.0024,00017,040.00
20/06/2018PurchaseDr. Frank Murdoch Armstrong75.0013,3009,975.00
20/06/2018PurchaseMr. Yrjo Erik Kristian Wichmann67.005,2003,484.00

Company Profile

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medicalconditions. The company currently has a pipeline focusing on acute organ traumas,vascular damage and cancer immunotherapy.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 06/09/2018

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-307.20
Op Mrgn0.00
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive Director, ChairmanDr. Frank Murdoch Armstrong
Non-Executive DirectorDr. Jonathan Kenneth Charles Knowles
Non-Executive Director, Vice ChairmanMr. Matti Esa Manner
Non-Executive DirectorMr. Leopoldo Giampaolo Zambeletti
Executive Director, Chief Executive OfficerDr. Markku Tapani Jalkanen
Executive Director, Chief Financial OfficerMr. Yrjo Erik Kristian Wichmann
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.